Cited by 2,770Cancer Cells and MetastasisDrug Transport and Resistance MechanismsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 183 of the 188 references it cites were found in a registry or an index.

A view on drug resistance in cancer

Open access

Vasan, Neil, Baselga, José, Hyman, David M.·2019·Nature

DOI 10.1038/s41586-019-1730-1PMC PMC8008476

Open this paper in CoChat — free account Open PDF

Abstract

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures. We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel drugs and improved pharmacological principles that result in deeper responses; and the identification of cancer cell dependencies by high-throughput synthetic lethality screens, integration of clinico-genomic data and computational modelling. These different approaches could eventually be synthesized for each tumour at any decision point and used to inform the choice of therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1730-1

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression.
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

Show all 188 references

Research works printed but not linked: 1

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).

Sorted by citations

Items 401–500 of 1,001

Transcription Regulation and Genome Rewiring Governing Sensitivity and Resistance to FOXM1 Inhibition in Breast Cancer
Ziegler, Y., Guillen, V. S., Kim, S. H., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (2021) · Cancers · doi:10.3390/cancers13246282 · Cited by 43
Photothermal agents based on small organic fluorophores with intramolecular motion
Lv, F., Fan, X., Liu, D., & Song, F. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.07.004 · Cited by 43
Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies
Wu, W., Xue, X., Chen, Y., Zheng, N., & Wang, J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106456 · Cited by 43
Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition
Tao, S., Liang, S., Zeng, T., & Yin, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1043667 · Cited by 46
An ultrasound assisted, ionic liquid-molecular iodine synergy driven efficient green synthesis of pyrrolobenzodiazepine-triazole hybrids as potential anticancer agents
Saquib, M., Ahamad, S., Khan, M. F., Khan, M. I., & Hussain, M. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1168566 · Cited by 43
Emerging diversity in extracellular vesicles and their roles in cancer
Sohal, I. S., & Kasinski, A. L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1167717 · Cited by 44
Probiotic-Derived Bioactive Compounds in Colorectal Cancer Treatment
Thoda, C., & Touraki, M. (2023) · Microorganisms · doi:10.3390/microorganisms11081898 · Cited by 49
Historical Perspective and Current Trends in Anticancer Drug Development
Gach, K., Drogosz-Stachowicz, J., Janecka, A. E., Wtorek, K., & Mirowski, M. (2024) · Cancers · doi:10.3390/cancers16101878 · Cited by 47
CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer
Zhong, C., Jiang, W., Yao, Y., Li, Z., Li, Y., Wang, S., Wang, X., Zhu, W., Wu, S., Wang, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49673-4 · Cited by 43
Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers
Nyen, T. V., Planque, M., van Wagensveld, L., Duarte, J. A. G., Zaal, E. A., Talebi, A., Rossi, M., Körner, P.-R., Rizzotto, L., Moens, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32272-6 · Cited by 45
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Aleksakhina, S. N., & Imyanitov, E. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010931 · Cited by 41
PARP-1-Associated Pathological Processes: Inhibition by Natural Polyphenols
Maluchenko, N. V., Feofanov, A. V., & Studitsky, V. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111441 · Cited by 42
A Lysosome-Targeting Self-Condensation Prodrug-Nanoplatform System for Addressing Drug Resistance of Cancer
Hou, D., Wang, M., Zhang, N.-Y., Xu, S., Wang, Z., Hu, X., Lv, G., Wang, J., Lv, M.-Y., Li, Y., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c00540 · Cited by 42
Advanced Cellular Models for Preclinical Drug Testing: From 2D Cultures to Organ-on-a-Chip Technology
Foglizzo, V., Cocco, E., & Marchiò, S. (2022) · Cancers · doi:10.3390/cancers14153692 · Cited by 48
Curcumin and Its Analogs in Non-Small Cell Lung Cancer Treatment: Challenges and Expectations
Tang, C., Liu, J., Yang, C., Ma, J., Chen, X., Liu, D., Zhou, R., Zhou, W., Lin, Y., & Yuan, X. (2022) · Biomolecules · doi:10.3390/biom12111636 · Cited by 42
Precise Starving Therapy via Physiologically Dependent Photothermal Conversion Promoted Mitochondrial Calcification Based on Multi‐Functional Gold Nanoparticles for Effective Tumor Treatment
Chang, X., Tang, X., Liu, J., Zhu, Z., Mu, W., Tang, W., Zhang, Y., & Chen, X. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202303596 · Cited by 42
The emerging roles of ac4C acetylation “writer” NAT10 in tumorigenesis: A comprehensive review
Wang, L., Tao, Y., Zhai, J., Xue, M., Zheng, C., & Hu, H. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127789 · Cited by 42
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Zhou, L., Lu, Y., Liu, W., Wang, S., Wang, L., Zheng, P., Zi, G., Liu, H., Liu, W., & Wei, S. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00493-8 · Cited by 44
Custom‐Design of Multi‐Stimuli‐Responsive Degradable Silica Nanoparticles for Advanced Cancer‐Specific Chemotherapy
Zhang, J., Zhou, J., Tang, L., Ma, J., Wang, Y., Yang, H. Y., Wang, X., & Fan, W. (2024) · Small · doi:10.1002/smll.202400353 · Cited by 45
Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer
Pfeifer, M., Brammeld, J. S., Price, S., Pilling, J. E., Bhavsar, D., Farcas, A. M., Bateson, J., Sundarrajan, A., Miragaia, R. J., Guan, N., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06190-w · Cited by 43
Cancer-on-a-chip for precision cancer medicine
Liu, L., Wang, H., Chen, R., Song, Y., Wei, W., Baek, D. S. H., Gillin, M., Kurabayashi, K., & Chen, W. (2025) · Lab on a Chip · doi:10.1039/d4lc01043d · Cited by 48
Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries
Rocha, C. R. R., Rocha, A. R., Silva, M. M., Gomes, L. R., Latância, M. T., Andrade-Tomaz, M., de Souza, I., Monteiro, L. K. S., & Menck, C. F. M. (2020) · Cells · doi:10.3390/cells9122573 · Cited by 42
Degradable and Excretable Ultrasmall Transition Metal Selenide Nanodots for High‐Performance Computed Tomography Bioimaging‐Guided Photonic Tumor Nanomedicine in NIR‐II Biowindow
Dong, L., Sun, L., Li, W., Jiang, Y., Zhan, Y., Yu, L., Chen, Y., & Hong, G. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202008591 · Cited by 42
Near-infrared light triggered multi-hit therapeutic nanosystem for tumor specific photothermal effect amplified signal pathway regulation and ferroptosis
Lian, H., Guan, P., Tan, H., Zhang, X., & Meng, Z. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.07.014 · Cited by 42
Nanoengineering a Zeolitic Imidazolate Framework‐8 Capable of Manipulating Energy Metabolism against Cancer Chemo‐Phototherapy Resistance
Lu, S., Tian, H., Li, L., Li, B., Yang, M. X., Zhou, L., Jiang, H., Li, Q., Wang, W., Nice, E. C., et al. (2022) · Small · doi:10.1002/smll.202204926 · Cited by 44
A biomimetic liver cancer on-a-chip reveals a critical role of LIPOCALIN-2 in promoting hepatocellular carcinoma progression
Shen, P., Jia, Y., Zhou, W., Zheng, W., Wu, Y., Qu, S., Du, S., Wang, S., Shi, H., Sun, J., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.04.010 · Cited by 42
New Technologies Bloom Together for Bettering Cancer Drug Conjugates
Jin, Y., Zakeri, S. E., Bahal, R., & Wiemer, A. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000499 · Cited by 42
Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells
He, C., Ali, D. J., Qi, Y., Li, Y., Sun, B., Liu, R., Sun, B., & Xiao, Z. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01902-6 · Cited by 40
Luteolin inhibits triple-negative breast cancer by inducing apoptosis and autophagy through SGK1-FOXO3a-BNIP3 signaling
Wu, L., Lin, Y., Gao, S., Wang, Y., Pan, H., Wang, Z., Pozzolini, M., Yang, F., Zhang, H., Yang, Y. L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1200843 · Cited by 41
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs
Zhao, Q., Zong, H., Zhu, P., Su, C., Tang, W., Chen, Z., & Jin, S. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00474-x · Cited by 47
Engineered Microorganisms for Advancing Tumor Therapy
Jia, J., Wang, X., Lin, X., & Zhao, Y. (2024) · Advanced Materials · doi:10.1002/adma.202313389 · Cited by 45
Dual-acidity-labile polysaccharide-di-drugs conjugate for targeted cancer chemotherapy
Li, D., Su, T., Ma, L., Yin, F., Xu, W., Ding, J., & Li, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112367 · Cited by 41
Targeting topoisomerase II with trypthantrin derivatives: Discovery of 7-((2-(dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione as an antiproliferative agent and to treat cancer
Catanzaro, E., Betari, N., Arencibia, J. M., Montanari, S., Sissi, C., Simone, A. D., Vassura, I., Santini, A., Andrisano, V., Tumiatti, V., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112504 · Cited by 41
Reshaping Antitumor Immunity with Chemo‐Photothermal Integrated Nanoplatform to Augment Checkpoint Blockade‐Based Cancer Therapy
Gao, T., Zhang, Z., Liang, S., Fu, S., Mu, W., Guan, L., Liu, Y., Chu, Q., Fang, Y., Liu, Y., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100437 · Cited by 41
Phyto-sesquiterpene lactones DET and DETD-35 induce ferroptosis in vemurafenib sensitive and resistant melanoma via GPX4 inhibition and metabolic reprogramming
Chang, M., Tsai, L., Nakagawa‐Goto, K., Lee, K., & Shyur, L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106148 · Cited by 41
Cell fusion in cancer hallmarks: Current research status and future indications (Review)
Wang, H., Xiang, W., Xue, B., Wang, Y., Yi, D., Jiang, X., Zhao, H., & Fu, P. (2021) · Oncology Letters · doi:10.3892/ol.2021.12791 · Cited by 43
The regulation of PBXs and their emerging role in cancer
Liu, Y., Ao, X., Zhou, X., Du, C., & Kuang, S. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17196 · Cited by 37
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
Fan, J., Ye, Y., Yan, L., Yuan, Y., Sun, B., Yang, D., Liu, N., Guo, J., Zhang, J., & Zhao, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01467-9 · Cited by 40
Reprogramming exosomes for immunity-remodeled photodynamic therapy against non-small cell lung cancer
Guo, J., Zhao, W., Xiao, X., Liu, S., Liu, L., La, Z., Lü, L., Li, Z., Li, Z., Xu, M., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.05.030 · Cited by 40
Controlled release of manganese and magnesium ions by microsphere-encapsulated hydrogel enhances cancer immunotherapy
Ma, L., Wang, X., Wu, Y., Zhang, Y., Yuan, X., Mao, J., Li, Q., & Gong, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.067 · Cited by 40
Biomimetic nanocarriers in cancer therapy: based on intercellular and cell-tumor microenvironment communication
He, M., Li, A., Gu, Y., Qingqing, C., Huanhuan, C., Xiaoyan, L., & Jiyong, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02835-4 · Cited by 45
Artificial Intelligence-Based Methods for Drug Repurposing and Development in Cancer
Herráiz-Gil, S., Nygren-Jiménez, E., Acosta-Alonso, D. N., León, C., & Guerrero‐Aspizua, S. (2025) · Applied Sciences · doi:10.3390/app15052798 · Cited by 47
Smart strategies to overcome tumor hypoxia toward the enhancement of cancer therapy
Xu, M., Wang, P., Sun, S., Gao, L., Sun, L., Zhang, L., Zhang, J., Wang, S., & Liang, X. (2020) · Nanoscale · doi:10.1039/d0nr05501h · Cited by 40
In‐vitro and In‐vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) Photocatalysts
Huang, C., Liang, C., Sadhukhan, T., Banerjee, S., Fan, Z., Li, T., Zhu, Z., Zhang, P., Raghavachari, K., & Huang, H. (2021) · Angewandte Chemie · doi:10.1002/ange.202015671 · Cited by 40
The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers
Zhang, X., Luo, M., Zhang, J., Guo, B., Singh, S., Lin, X., Xiong, H., Ju, S., Wang, L., Zhou, Y., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1005522 · Cited by 40
Tumor-associated neutrophils: orchestrating cancer pathobiology and therapeutic resistance
Bui, T. M., Yalom, L. K., & Sumagin, R. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1954162 · Cited by 42
A Cascade Targeted and Mitochondrion-Dysfunctional Nanomedicine Capable of Overcoming Drug Resistance in Hepatocellular Carcinoma
Yang, Y., Mai, Z., Zhang, Y., Yu, Z., Li, W., Zhang, Y., Li, F., Timashev, P. S., Luan, P., Luo, D., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c09342 · Cited by 40
PEGylated Manganese–Zinc Ferrite Nanocrystals Combined with Intratumoral Implantation of Micromagnets Enabled Synergetic Prostate Cancer Therapy via Ferroptotic and Immunogenic Cell Death
Wang, H., Guan, Y., Li, C., Chen, J., Yue, S., Qian, J., Dai, B., Jiang, C., Wen, C., Wen, L., et al. (2023) · Small · doi:10.1002/smll.202207077 · Cited by 40
Sniping Cancer Stem Cells with Nanomaterials
Wang, W.-D., Guo, Y., Yang, Z., Su, G.-L., & Sun, Z. (2023) · ACS Nano · doi:10.1021/acsnano.3c07828 · Cited by 38
Inorganic sonosensitizer nanomaterials for sonodynamic therapy of diseases beyond cancer
Sosnik, A., Zlotver, I., & Potthuri, H. (2024) · Progress in Materials Science · doi:10.1016/j.pmatsci.2024.101384 · Cited by 39
Intracellular aggregation of peptide-reprogrammed small molecule nanoassemblies enhances cancer chemotherapy and combinatorial immunotherapy
Peng, J., Xiao, Y., Yang, Q., Liu, Q., Chen, Y., Shi, K., Hao, Y., Han, R., & Qian, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.06.013 · Cited by 40
Immune Landscape of the Tumor Microenvironment Identifies Prognostic Gene Signature CD4/CD68/CSF1R in Osteosarcoma
Song, Y., Xu, Y., Zhu, X., Fu, J., Deng, C., Chen, H., Xu, H., Song, G., Lu, J., Tang, Q., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01198 · Cited by 41
Evolving insights: how DNA repair pathways impact cancer evolution
Zhou, J., Zhou, X. A., Zhang, N., & Wang, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0177 · Cited by 40
Water soluble ionic Co( ii ), Cu( ii ) and Zn( ii ) diimine–glycinate complexes targeted to tRNA: structural description, in vitro comparative binding, cleavage and cytotoxic studies towards chemoresistant prostate cancer cells
Zehra, S., Gómez‐Ruiz, S., Siddique, H. R., Tabassum, S., & Arjmand, F. (2020) · Dalton Transactions · doi:10.1039/d0dt02657c · Cited by 39
Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer
Malier, M., Court, M., Gharzeddine, K., Laverierre, M.-H., Marsili, S., Thomas, F., Decaens, T., Roth, G. S., & Millet, A. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1572 · Cited by 40
DualGCN: a dual graph convolutional network model to predict cancer drug response
Ma, T., Liu, Q., Li, H., Zhou, M., Jiang, R., & Zhang, X. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04664-4 · Cited by 40
Liposomal Nanoformulation as a Carrier for Curcumin and pEGCG—Study on Stability and Anticancer Potential
Piwowarczyk, L., Kucińska, M., Tomczak, S., Młynarczyk, D. T., Piskorz, J., Gośliński, T. A., Murias, M., & Jelińska, A. (2022) · Nanomaterials · doi:10.3390/nano12081274 · Cited by 41
Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs
Bartolucci, D., Pession, A., Hrelia, P., & Tonelli, R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071453 · Cited by 43
Surface-Engineered Chlorella Alleviated Hypoxic Tumor Microenvironment for Enhanced Chemotherapy and Immunotherapy of First-Line Drugs
Gao, C., Kwong, C. H. T., Wang, Q., Kam, H., Wei, J., Chen, Q., Zhang, J., Lee, S. M. Y., Gu, D., & Wang, R. (2022) · Materials Today · doi:10.1016/j.mattod.2022.06.024 · Cited by 39
The Role of RNA Modifications and RNA-modifying Proteins in Cancer Therapy and Drug Resistance
Wood, S., Willbanks, A. R., & Cheng, J. X. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210127092828 · Cited by 37
3D bioprinting and the revolution in experimental cancer model systems—A review of developing new models and experiences with in vitro 3D bioprinted breast cancer tissue-mimetic structures
Sztankovics, D., Moldvai, D., Petővári, G., Gelencsér, R., Krencz, I., Raffay, R. E., Dankó, T., & Sebestyén, A. R. (2023) · Pathology & Oncology Research · doi:10.3389/pore.2023.1610996 · Cited by 39
HMGA2 regulation by miRNAs in cancer: Affecting cancer hallmarks and therapy response
Hashemi, M., Rashidi, M., Hushmandi, K., ten Hagen, T. L. M., Salimimoghadam, S., Taheriazam, A., Entezari, M., & Falahati, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106732 · Cited by 38
Polyoxometalates as Potential Artificial Enzymes toward Biological Applications
Li, B., Xu, X., Lv, Y., Wu, Z., He, L., & Song, Y. (2023) · Small · doi:10.1002/smll.202305539 · Cited by 38
Thioamides in medicinal chemistry and as small molecule therapeutic agents
Huang, G., Cierpicki, T., & Grembecka, J. E. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116732 · Cited by 38
Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma
Kuznetsoff, J. N., Owens, D. A., Lopez, A., Rodriguez, D. A., Chee, N. T., Kurtenbach, S., Bilbao, D., Roberts, E. R., Volmar, C., Wahlestedt, C., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0434 · Cited by 41
CpACpP: In Silico Cell-Penetrating Anticancer Peptide Prediction Using a Novel Bioinformatics Framework
Nasiri, F., Atanaki, F. F., Behrouzi, S., Kavousi, K., & Bagheri, M. (2021) · ACS Omega · doi:10.1021/acsomega.1c02569 · Cited by 38
Injectable and self-healing nanocomposite hydrogel loading needle-like nano-hydroxyapatite and graphene oxide for synergistic tumour proliferation inhibition and photothermal therapy
Qi, Y., Qian, Z., Yuan, W., & Li, Z. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb01753e · Cited by 38
The molecular mechanism of METTL3 promoting the malignant progression of lung cancer
Ma, C., Ma, R., Hu, K., Zheng, Q., Wang, Y.-P., Zhang, N., & Sun, Z. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02539-5 · Cited by 38
Homogeneous antibody and CAR-T cells with improved effector functions targeting SSEA-4 glycan on pancreatic cancer
Lin, C.-W., Wang, Y.-J., Lai, T.-Y., Hsu, T.-L., Han, S.-Y., Wu, H., Shen, C., Dang, V., Chen, M. W., Chen, L.-B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114774118 · Cited by 36
A self-amplified ferroptosis nanoagent that inhibits the tumor upstream glutathione synthesis to reverse cancer chemoresistance
Yang, C., Chen, Z., Wei, M., Hu, S., Cai, M., Wang, N., Guan, Y., Li, F., Ding, Q., & Ling, D. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.030 · Cited by 39
Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy
Zhang, Y., Zhang, Y., Tao, H., Zhu, J., Lu, Y., Cheng, F., Xiong, Y., Liu, J., Cai, G., Zhang, Z., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216405 · Cited by 37
Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability
Feng, Y., Lee, J., Yang, L., Hilton, M. B., Morris, K., Seaman, S., Edupuganti, V. V. S. R., Hsu, K.-S., Dower, C. M., Yu, G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113503 · Cited by 37
Targeting metabolic reprogramming in hepatocellular carcinoma to overcome therapeutic resistance: A comprehensive review
Wang, Q., Liu, J., Chen, Z., Zheng, J., Wang, Y., & Dong, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116021 · Cited by 44
c-Fos regulated by TMPO/ERK axis promotes 5-FU resistance via inducing NANOG transcription in colon cancer
Gui, Y., Qian, X., Ding, Y., Chen, Q., Ye, F., Ye, Y., Hou, Y., Yu, J., & Zhao, L. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06451-w · Cited by 37
Plant-derived extracellular vesicles as a promising anti-tumor approach: A comprehensive assessment of effectiveness, safety, and mechanisms
Qiang, W., Li, J., Ruan, R., Li, Q., Zhang, X., Yan, A., & Zhu, H. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155750 · Cited by 37
mTORC2-driven chromatin cGAS mediates chemoresistance through epigenetic reprogramming in colorectal cancer
Lv, G., Wang, Q., Lin, L., Ye, Q., Li, X., Zhou, Q., Kong, X., Deng, H., You, F., Chen, H., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01473-0 · Cited by 40
A protracted war against cancer drug resistance
Tian, Y., Wang, X., Wu, C., Qiao, J., Jin, H. D., & Li, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03510-2 · Cited by 39
Unfolded Protein Response in Leukemia: From Basic Understanding to Therapeutic Opportunities
Khateb, A., & Ronai, Z. A. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.05.012 · Cited by 38
Multifunctional Role of Astrocyte Elevated Gene-1 (AEG-1) in Cancer: Focus on Drug Resistance
Manna, D., & Sarkar, D. (2021) · Cancers · doi:10.3390/cancers13081792 · Cited by 38
Hyaluronic acid-based nanogels derived from multicomponent self-assembly for imaging-guided chemo-photodynamic cancer therapy
Pan, Y., Ding, Y., Han, Z., Yuwen, L., Zhan, Y., Mok, G. S. P., Li, S., & Wang, L. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118257 · Cited by 37
Circular RNA circ_0006168 enhances Taxol resistance in esophageal squamous cell carcinoma by regulating miR-194-5p/JMJD1C axis
Qu, F.-Y., Wang, L., Wang, C., Yu, L., Zhao, K., & Zhong, H. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01984-y · Cited by 37
A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy
Zhu, D., Zhang, H., Huang, Y., Lian, B., Ma, C., Han, L., Chen, Y., Wu, S., Li, N., Zhang, W., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071092 · Cited by 37
Ruthenium (II)‐Coordinated Supramolecular Metallodrug Complex Realizing Oxygen Self‐Supply In Situ for Overcoming Hypoxic Tumors
Liu, C., Li, M., Li, P., Bai, Y., Pang, J., Fan, L., & Tian, W. J. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202105837 · Cited by 39
The emerging role of selenium metabolic pathways in cancer: New therapeutic targets for cancer
Kalishwaralal, K., Keerthana, C. K., Mohan, M., Arivalagan, J., Christyraj, J. R. S. S., Firer, M. A., Choudry, H. A., Anto, R. J., & Lee, Y. J. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30196 · Cited by 40
Autophagy Modulation and Cancer Combination Therapy: A Smart Approach in Cancer Therapy
Jeda, A. S., Ghabeshi, S., pour, Z. G. M., Jazaeri, E. O., Araiinejad, M., Sheikholeslami, F., Abdoli, M., Edalat, M., & Abdoli, A. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100512 · Cited by 38
Application of organic frame materials in cancer therapy through regulation of tumor microenvironment
Yao, S., Wang, Z., & Li, L. (2022) · Smart Materials in Medicine · doi:10.1016/j.smaim.2022.01.006 · Cited by 37
Gut microbiota, an emergent target to shape the efficiency of cancer therapy
Kouidhi, S., Zidi, O., Belkhiria, Z., Raïs, H., Ayadi, A., Ayed, F. B., Mosbah, A., Cherif, A., & Gaaied, A. B. A. E. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00132 · Cited by 37
Insights on the Role of Polyphenols in Combating Cancer Drug Resistance
Farhan, M. (2023) · Biomedicines · doi:10.3390/biomedicines11061709 · Cited by 38
Colorectal cancer and therapy response: a focus on the main mechanisms involved
Tirendi, S., Marengo, B., Domenicotti, C., Bassi, A. M., Almonti, V., & Vernazza, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1208140 · Cited by 37
Liposomes for Cancer Theranostics
Fernandes, D. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102448 · Cited by 38
Aryl hydrocarbon receptor sulfenylation promotes glycogenolysis and rescues cancer chemoresistance
Zhou, N., Chen, J., Zheng, L., Zhang, C., Zhou, Y., Wang, D., Zhou, L., Wang, Z., Sun, N., Wang, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170753 · Cited by 36
Hypoxia-associated autophagy flux dysregulation in human cancers
Fu, J., Lin, J., Dai, Z., Lin, B., & Zhang, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216823 · Cited by 37
Glutathione‐Sensitive Photosensitizer–Drug Conjugates Target the Mitochondria to Overcome Multi‐Drug Resistance in Cancer
Song, W., Yang, H., Wang, Y., Chen, S., Zhong, W., Wang, Q., Ding, W., Xu, G., Chen, M., Liang, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202307765 · Cited by 36
The emerging roles of platelet-derived extracellular vesicles in disease
Lou, C., & Cai, X. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2499029 · Cited by 38
Epigenetic Heritability of Cell Plasticity Drives Cancer Drug Resistance through a One-to-Many Genotype-to-Phenotype Paradigm
de Oliveira, E. A., Milite, S., Fernández-Mateos, J., Cresswell, G. D., Romero, E. Y., Vlachogiannis, G., Chen, B., James, C. T., Patruno, L., Ascolani, G., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0999 · Cited by 46
How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs
Garofalo, M., Grazioso, G., Cavalli, A., & Sgrignani, J. (2020) · Molecules · doi:10.3390/molecules25071756 · Cited by 39
Design, Synthesis and Biological Evaluation of New Pyrimidine Derivatives as Anticancer Agents
Madia, V. N., Nicolai, A., Messore, A., Leo, A. D., Ialongo, D., Tudino, V., Saccoliti, F., Vita, D. D., Scipione, L., Artico, M., et al. (2021) · Molecules · doi:10.3390/molecules26030771 · Cited by 36
Pluripotent Stem Cells: Cancer Study, Therapy, and Vaccination
Barati, M., Akhondi, M., Mousavi, N. S., Haghparast, N., Ghodsi, A., Baharvand, H., Ebrahimi, M., & Hassani, S. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10199-7 · Cited by 36
Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
Zañudo, J. G. T., Mao, P., Alcon, C., Kowalski, K. J., Johnson, G. N., Xu, G., Baselga, J. M., Scaltriti, M., Letai, A. G., Montero, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1208 · Cited by 37
Self-citation
Banxia xiexin decoction affects drug sensitivity in gastric cancer cells by regulating MGMT expression via IL‑6/JAK/STAT3‑mediated PD‑L1 activity
Feng, X., Xue, F., He, G., Ni, Q., & Huang, S. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4998 · Cited by 36

Authors: Vasan, N., Baselga, J., & Hyman, D. M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Hyman, David M.
ORCID: Vasan, Neil
Hyman, David M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2019-11-13
Volume: 575
Issue: 7782
Pages: 299-309
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-019-1730-1
PMC: PMC8008476
OpenAlex: W2988773550
Cited by: 2,770
References: 188
Citations by year: 2026: 344 · 2025: 533 · 2024: 524 · 2023: 467 · 2022: 397 · 2021: 346 · 2020: 150 · 2019: 4
FWCI: 21.44
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Eli Lilly and Company
National Cancer Institute (R01CA207244, R01CA190642, P30CA008748, T32CA009207)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: chemoresistance, tumor heterogeneity, tumor microenvironment, tumor immune evasion, tumor growth kinetics, tumor burden, early cancer detection, adaptive monitoring, synthetic lethality screen, precision oncology
MeSH terms: Antineoplastic Agents, Humans, Models, Biological, Neoplasms, Drug Resistance, Neoplasm, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A view on drug resistance in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks